← Back to Search

CBT + ImRs for Post-Traumatic Stress Disorder

Phase 2 & 3

Waitlist Available

Research Sponsored by Boston University Charles River Campus

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up change from baseline to 4 weeks (post-treatment), 5 weeks (1-week follow-up) and 9 weeks (1-month follow-up)

Awards & highlights

Study Summary

This trial will study whether a drug can enhance the effect of a new psychological intervention for people with PTSD symptoms.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ change from baseline to 4 weeks (post-treatment), 5 weeks (1-week follow-up) and 9 weeks (1-month follow-up)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~change from baseline to 4 weeks (post-treatment), 5 weeks (1-week follow-up) and 9 weeks (1-month follow-up)

This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline to 4 weeks (post-treatment), 5 weeks (1-week follow-up) and 9 weeks (1-month follow-up) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

The Clinician-Administered PTSD Scale (CAPS)

Secondary outcome measures

Anxiety

PTSD Checklist for DSM-5 (PCL-5)

Pittsburgh Sleep Quality Index (PSQI)

+3 more

Trial Design

3Treatment groups

Experimental Treatment

Active Control

Group I: CBT + ImRs + DCS pillExperimental Treatment2 Interventions

The experimental arm involves cognitive-behavioral therapy, imagery rescripting techniques and d-cycloserine medication (pill).

Group II: CBT + ImRs + placeboActive Control2 Interventions

The active comparator arm involves cognitive behavioral therapy, imagery rescripting techniques and placebo medication (pill).

Group III: CBT + I.E. + study pillActive Control2 Interventions

The placebo comparator involves cognitive behavioral therapy, imaginal exposure and study pill (DCS or placebo)

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Cycloserine

FDA approved

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

James S McDonnell FoundationOTHER

4 Previous Clinical Trials

258 Total Patients Enrolled

Boston University Charles River CampusLead Sponsor

113 Previous Clinical Trials

12,161 Total Patients Enrolled

Joseph K Carpenter, M.A.Study ChairBoston University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is it possible to sign up for this clinical trial at the moment?

"That is accurate. The clinical trial indicated on clinicaltrials.gov is currently looking for patients. This study was originally posted on September 1st, 2016 and was last edited on July 19th, 2021. They are hoping to find 60 patients at 1 location."

Answered by AI

What other research studies have looked at the combination of CBT and ImRs?

"At this time, there are 9 ongoing clinical trials testing the efficacy of CBT + ImRs with 2 of those in Phase 3. A majority of these tests are being conducted in Baltimore, Maryland; however, 23 different centres across the country are running similar studies."

Answered by AI

What psychological disorders can CBT + ImRs help alleviate?

"Cognitive behavioral therapy in conjunction with ImRs is the standard of care for patients that have not responded to other forms of treatment. It can also be used to help those suffering from tuberculosis, extrapulmonary tuberculosis, and pulmonary tuberculosis."

Answered by AI

How many individuals are included in this clinical trial?

"That is correct, the online information from clinicaltrials.gov affirms that this study needs more patients and is currently recruiting. The posting date was September 1st 2016 with the most recent update on July 19th 2021. They are looking for a total of 60 participants spread out across 1 location."

Answered by AI

Recent research and studies

American Journal of PsychiatryJournal

<scp>d</scp>-cycloserine as an Augmentation Strategy with Cognitive-behavioral Therapy for Social Anxiety Disorder

Hofmann, Stefan G., Jasper A.J. Smits, David Rosenfield, Naomi Simon, Michael W. Otto, Alicia E. Meuret, Luana Marques, Angela Fang, Candyce Tart, and Mark H. Pollack. 2013. “d-cycloserine as an Augmentation Strategy with Cognitive-behavioral Therapy for Social Anxiety Disorder”. American Journal of Psychiatry. American Psychiatric Association Publishing. doi:10.1176/appi.ajp.2013.12070974.

Journal of Psychiatric ResearchJournal

A Randomized Placebo-controlled Trial of D-cycloserine and Exposure Therapy for Posttraumatic Stress Disorder

Litz, Brett T., Kristalyn Salters-Pedneault, Maria M. Steenkamp, John A. Hermos, Richard A. Bryant, Michael W. Otto, and Stefan G. Hofmann. 2012. “A Randomized Placebo-controlled Trial of D-cycloserine and Exposure Therapy for Posttraumatic Stress Disorder”. Journal of Psychiatric Research. Elsevier BV. doi:10.1016/j.jpsychires.2012.05.006.

Behaviour Research and TherapyJournal

Treatment of Childhood Memories: Theory and Practice

Arntz, Arnoud, and Anoek Weertman. 1999. “Treatment of Childhood Memories: Theory and Practice”. Behaviour Research and Therapy. Elsevier BV. doi:10.1016/s0005-7967(98)00173-9.

Journal of Behavior Therapy and Experimental PsychiatryJournal